Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.51 |
| ▸ | KDM5B | Q9UGL1 | 3/20 | 0.50 |
| ▸ | KDM5A | P29375 | 2/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 3/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.42 |
| ▸ | USP19 | O94966 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | TACR3 | P29371 | 1/20 | 0.39 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16034277 | 0.74 | KDM5B (0.65) | PHF8KDM5BKDM5ACYP17A1KDM4C | |
| SCHEMBL18081014 | 0.71 | KDM5B (0.50) | PHF8KDM5BKDM5ACYP11B1CYP11B2 | |
| SCHEMBL13780324 | 0.71 | HRH4 (0.51) | PHF8KDM5BKDM5AFYNHRH4 | |
| SCHEMBL28748054 | 0.70 | CYP17A1 (0.38) | CYP11B1CYP11B2CYP17A1FYNHRH4 | |
| SCHEMBL18038826 | 0.69 | KDM5B (0.49) | PHF8KDM5BKDM5ACYP11B1CYP11B2 | |
| SCHEMBL20009013 | 0.69 | KDM5B (0.49) | PHF8KDM5BKDM5ACYP11B1CYP11B2 | |
| SCHEMBL18081023 | 0.69 | KDM5B (0.49) | PHF8KDM5BKDM5ACYP11B1CYP11B2 | |
| SCHEMBL28776455 | 0.69 | KDM5B (0.49) | PHF8KDM5BKDM5ACYP11B1CYP11B2 | |
| SCHEMBL27744440 | 0.69 | KDM5B (0.49) | PHF8KDM5BKDM5ACYP11B1CYP11B2 | |
| SCHEMBL27744439 | 0.69 | KDM5B (0.49) | PHF8KDM5BKDM5ACYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1194144-B1 | ANTIBACTERIAL COMPOUNDS | AFFINIUM PHARM INC (CA) | 2006-11-02 | — | — | EP | claimed |
| US-20030149089-A1 | Antibacterial compounds | SMITHKLINE BEECHAM CORPORATION | 2003-08-07 | — | — | US | claimed |
| JP-2003500357-A | — | — | 2003-01-07 | — | — | JP | claimed |
| EP-1194144-A4 | ANTIBACTERIAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2002-08-07 | — | — | EP | claimed |
| EP-1194144-A1 | ANTIBACTERIAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-04-10 | — | — | EP | claimed |
| WO-2000071120-A1 | ANTIBACTERIAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-11-30 | — | — | WO | claimed |
| EP-1194144-B1 | ANTIBACTERIAL COMPOUNDS | AFFINIUM PHARM INC (CA) | 2006-11-02 | — | — | EP | disclosed |
| US-6673941-B2 | Disubstituted imidazoles useful in the treatment of bacterial infections | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2004-01-06 | — | — | US | disclosed |
| US-20030149089-A1 | Antibacterial compounds | SMITHKLINE BEECHAM CORPORATION | 2003-08-07 | — | — | US | disclosed |
| US-6559172-B1 | Treatment of bacterial infections, particularly through the inhibition of FAB I. and antiobiotics | SMITHKLINE BEECHAM CORPORATION | 2003-05-06 | — | — | US | disclosed |
| EP-1194144-A4 | ANTIBACTERIAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2002-08-07 | — | — | EP | disclosed |
| EP-1194144-A1 | ANTIBACTERIAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-04-10 | — | — | EP | disclosed |
| WO-2000071120-A1 | ANTIBACTERIAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149089-A1 | Antibacterial compounds | MRPL21, MRPS28, SPOUT1 | PHF8 4427/4885KDM5B 4450/4885KDM5A 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.